Enclomiphene and Primobolan Interaction

Avoid
Mechanism-based 64% confidence

Enclomiphene and Primobolan have a potentially harmful interaction with 64% confidence. Both Enclomiphene and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads, so monitoring these systems is recommended.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Half-life: ~10 hours Typical dose: 12.5-25mg oral daily pct, sexual health
estrogen receptorserotonin receptor hepatotoxicpct agentteratogenic
View full profile

Primobolan

Anabolic Steroid | Lean Mass & Low Side Effect Profile

Metenolone binds to the androgen receptor (AR) to promote nitrogen retention, protein synthesis, and anti-catabolic effects in skeletal muscle tissue. As a DHT derivative, it cannot be aromatized by the aromatase enzyme, meaning it produces no estrogenic metabolites and does not contribute to water retention, gynecomastia, or estrogen-mediated fat gain.

Half-life: ~10 days (enanthate) Typical dose: 400-800 mg/week (injectable) or 50-100 mg/day (oral) anabolic
5 alpha reductaseandrogen receptoraromataseepo receptor androgenicblood pressure raisingcarcinogenic riskhepatotoxic
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pituitary
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Enclomiphene, Primobolan). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 compounds share the teratogenic safety flag (Enclomiphene, Primobolan). Monitor accordingly.

Frequently Asked Questions

Can I take Enclomiphene with Primobolan?

Combining Enclomiphene with Primobolan is not recommended. Both Enclomiphene and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Enclomiphene and Primobolan safe together?

This combination carries significant risk. Both Enclomiphene and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Enclomiphene and Primobolan?

Both Enclomiphene and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Enclomiphene and Primobolan?

Enclomiphene has a half-life of ~10 hours and Primobolan has a half-life of ~10 days (enanthate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Enclomiphene vs Primobolan

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.